Jaguar Health Inc. announced it has entered into privately negotiated exchange agreements with Iliad Research and Trading, L.P. and Streeterville, involving the exchange of outstanding royalty interests and preferred stock for pre-funded common stock purchase warrants. Specifically, Jaguar issued a pre-funded warrant to Iliad to purchase 1,553,844 shares of common stock in exchange for a $1,187,914.07 reduction in the balance of a previously issued royalty interest. Additionally, the company exchanged 22 shares of Series L Preferred Stock held by Iliad for a warrant to purchase 719,424 shares of common stock, resulting in the cancellation and retirement of those preferred shares. The transactions are intended to reduce Jaguar’s outstanding royalty and preferred stock obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-021064), on January 23, 2026, and is solely responsible for the information contained therein.